Baidu
map

肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

JCO：ASCO与CAP更新乳腺癌HER2检测指南

2013-11-20 中国医学论坛报 中国医学论坛报

ASCOCAPHER2检测指南
关注

美国临床肿瘤学会(ASCO)和美国病理学医师学院(CAP)更新了乳腺癌HER2检测指南。新指南推荐应用免疫组织化学染色(IHC)或原位杂交(ISH)提高HER2检测准确率。HER2阳性标准为Her-2蛋白过表达(IHC，镜下视野>10%的相邻同质性肿瘤组织细胞区域)和基因扩增(ISH，组织内至少20个细胞可见HER2 拷贝或HER2:CEP17);检测结果若与其他组织学检测不符须重复检测;检

美国临床肿瘤学会(ASCO)和美国病理学医师学院(CAP)更新了乳腺癌HER2检测指南。新指南推荐应用免疫组织化学染色(IHC)或原位杂交(ISH)提高HER2检测准确率。

HER2阳性标准为Her-2蛋白过表达(IHC，镜下视野>10%的相邻同质性肿瘤组织细胞区域)和基因扩增(ISH，组织内至少20个细胞可见HER2 拷贝或HER2:CEP17);检测结果若与其他组织学检测不符须重复检测;检测实验室的检测结果应与经验证的HER2检测结果有高度一致性;检测要在CAP等机构认证的实验室进行。该研究在线发表于10月7日 J Clin Oncol。

原文出处：

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF.Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update.J Clin Oncol. 2013 Nov 1;31(31):3997-4013. doi: 10.1200/JCO.2013.50.9984. Epub 2013 Oct 7.【原文下载】

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1954181, encodeId=c75c1954181f7, content=<a href='/topic/show?id=56078e28be' target=_blank style='color:#2F92EE;'>#HER2检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8728, encryptionId=56078e28be, topicName=HER2检测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Aug 24 14:02:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891107, encodeId=b167189110e20, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Dec 15 08:02:00 CST 2013, time=2013-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938263, encodeId=2f07193826367, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Dec 08 19:02:00 CST 2013, time=2013-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897934, encodeId=4b8b189e934b4, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Aug 17 01:02:00 CST 2014, time=2014-08-17, status=1, ipAttribution=)]
    2014-08-24 仁医06

    #HER2检测#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1954181, encodeId=c75c1954181f7, content=<a href='/topic/show?id=56078e28be' target=_blank style='color:#2F92EE;'>#HER2检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8728, encryptionId=56078e28be, topicName=HER2检测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Aug 24 14:02:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891107, encodeId=b167189110e20, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Dec 15 08:02:00 CST 2013, time=2013-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938263, encodeId=2f07193826367, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Dec 08 19:02:00 CST 2013, time=2013-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897934, encodeId=4b8b189e934b4, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Aug 17 01:02:00 CST 2014, time=2014-08-17, status=1, ipAttribution=)]
    2013-12-15 lidong40

    #JCO#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1954181, encodeId=c75c1954181f7, content=<a href='/topic/show?id=56078e28be' target=_blank style='color:#2F92EE;'>#HER2检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8728, encryptionId=56078e28be, topicName=HER2检测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Aug 24 14:02:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891107, encodeId=b167189110e20, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Dec 15 08:02:00 CST 2013, time=2013-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938263, encodeId=2f07193826367, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Dec 08 19:02:00 CST 2013, time=2013-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897934, encodeId=4b8b189e934b4, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Aug 17 01:02:00 CST 2014, time=2014-08-17, status=1, ipAttribution=)]
    2013-12-08 一叶知秋

    #ASC#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1954181, encodeId=c75c1954181f7, content=<a href='/topic/show?id=56078e28be' target=_blank style='color:#2F92EE;'>#HER2检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8728, encryptionId=56078e28be, topicName=HER2检测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Aug 24 14:02:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891107, encodeId=b167189110e20, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Dec 15 08:02:00 CST 2013, time=2013-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938263, encodeId=2f07193826367, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Dec 08 19:02:00 CST 2013, time=2013-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897934, encodeId=4b8b189e934b4, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Aug 17 01:02:00 CST 2014, time=2014-08-17, status=1, ipAttribution=)]
    2014-08-17 smlt2008

    #CAP#

    0

相关资讯

ASCO发布烟草控制任务清单

  美国肿瘤医生正在呼吁联邦和各州政府加强对烟草产品的监管，增加对研究的资助，以及确保新的医疗保险交易体系覆盖戒烟治疗。 根据美国临床肿瘤学会(ASCO)发布的政策声明，临床医生还应当“以身作则”地不吸烟，积极治疗烟草依赖，为无烟环境摇旗呐喊，以及拒绝接受烟草企业的支持。该声明发表在7月29日的《临床肿瘤杂志》上(doi:10.1200/JCO.2013.48.8932)。这是ASC

BOA 2013：ASCO年会后主要肿瘤治疗策略

2013年7月13日下午，BOA2013大会临近尾声。会务组邀请沈琳教授、陆舜教授、江泽飞教授及李进教授在这一时段为与会者分享了胃癌、非小细胞肺癌、乳腺癌及肠癌的治疗策略。首先出场的沈琳教授回顾了过往一年临床胃癌领域取得的主要进展及其对临床实践的影响。在她看来2013年是胃癌研究的“小年”。目前取得的研究结果没有明显改变现有的规范和指南。不过，其潜在影响却很大。沈教授尤其强调了胃癌异质性给治疗带来

JCO：ASCO更新癌症患者静脉血栓栓塞防治指南

美国临床肿瘤学会（ASCO）近期更新癌症患者静脉血栓栓塞防治指南，认为“告知癌症患者其为静脉血栓栓塞（VTE）高危人群”是非常关键的事情，癌症患 者在接受化疗时即应进行VTE 风险评估。然而，指南并不建议门诊癌症患者常规预防性应用抗凝药物。 此次指南更新基于专家组对42项相关研究的回顾分析结果。专家组指出，分别于2010年和2011年发表的两项研究表明，近50%的癌症患者并不知晓其为

ASCO 2013：三阴性乳腺癌患者中TNBC亚型可预测患者对治疗的应答率

通过基因分析，Lehmann等的研究结果指出(J Clin Invest 121:2750-2767, 2011)三阴性乳腺癌能够被分为6个集群——基底细胞样1（BL1）、基底细胞样2（BL2）、免疫调节（IM）、间充质样细胞（M）、间充质样干细胞（MSL）和管样雄激素受体（LAR），以及不稳定的集群（UNS）。目前已知三阴性乳腺癌患者对化疗的治疗反应各不相同，但是不同亚型的三阴性乳腺癌患者和其对

ASCO 2013：贝伐珠单抗一线治疗无益于胶质瘤患者生存

一项双盲、安慰剂对照Ⅲ期试验结果显示，在胶质母细胞瘤一线放疗及替莫唑胺治疗的基础上加用贝伐珠单抗，并不能延长患者的生存期。放射治疗肿瘤学组(RTOG)0825研究显示贝伐珠单抗(阿瓦斯汀)可延长无进展生存期，但未能改善总生存期，而且这种血管生成抑制剂与更糟糕的神经认知和生活质量结局相关。 在美国临床肿瘤学会(ASCO)2013年会上，Mark R. Gilbert医生报告称，在随机分组接受治疗的

ASCO 2013：多柔比星联合环磷酰胺对早期乳腺癌患者的疗效优于紫杉醇

在对早期乳腺癌患者制定最佳辅助化疗方案时的主要决定因素是治疗方案的有效性和毒性反应。Lawrence N. Shulman等认为紫杉醇单药治疗的毒性反应要小于多柔比星联合环磷酰胺，为了确定这两种方案对早期乳腺患者的有效性是否一致，他们进行了研究并在ASCO2013上发表了他们的研究结果。 本研究为2*2的析因研究，研究所纳入的受试者为可经手术治疗的乳腺癌患者，并且其腋淋巴结阳性数在0-3之间

Baidu
map
Baidu
map
Baidu
map